Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-09
DOI
10.1186/s13045-022-01362-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- (2022) Ming Yi et al. Molecular Cancer
- Harnessing big data to characterize immune-related adverse events
- (2022) Ying Jing et al. Nature Reviews Clinical Oncology
- Immune-checkpoint inhibitors: long-term implications of toxicity
- (2022) Douglas B. Johnson et al. Nature Reviews Clinical Oncology
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
- (2022) Ruozheng Wei et al. CANCER RESEARCH
- Nivolumab Plus Relatlimab: First Approval
- (2022) Julia Paik DRUGS
- A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
- (2022) Alexander C. Huang et al. NATURE IMMUNOLOGY
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
- (2022) Vivek Narayan et al. NATURE MEDICINE
- Engineering the next generation of cell-based therapeutics
- (2022) Caleb J. Bashor et al. NATURE REVIEWS DRUG DISCOVERY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
- (2021) Neil T. Conlon et al. BRITISH JOURNAL OF CANCER
- Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
- (2021) Sandeep Pallerla et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 2020 FDA drug approvals
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Small-cell lung cancer
- (2021) Charles M. Rudin et al. Nature Reviews Disease Primers
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors
- (2021) Darren C Phillips et al. CANCER RESEARCH
- Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
- (2021) Yi-Long Wu et al. CANCER TREATMENT REVIEWS
- Inclisiran: First Approval
- (2021) Yvette N. Lamb DRUGS
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
- (2021) Rafal Dziadziuszko et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
- (2021) Francois Gonzalvez et al. Cancer Discovery
- Prostate cancer
- (2021) Richard J. Rebello et al. Nature Reviews Disease Primers
- Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
- (2021) Alexander Chehrazi-Raffle et al. Cancers
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
- (2021) Enrico Zelin et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
- (2021) Joost Neijssen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic strategies in RET gene rearranged non-small cell lung cancer
- (2021) Leylah M. Drusbosky et al. Journal of Hematology & Oncology
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- (2021) Evan Y Yu et al. LANCET ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- KSHV/HHV8-mediated hematologic diseases
- (2021) Ethel Cesarman et al. BLOOD
- Brain and other central nervous system tumor statistics, 2021
- (2021) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The ever‐increasing importance of cancer as a leading cause of premature death worldwide
- (2021) Freddie Bray et al. CANCER
- Microbiome and cancer
- (2021) Nyssa Cullin et al. CANCER CELL
- Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
- (2021) Cai Zhang et al. Cellular & Molecular Immunology
- KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms
- (2021) Shinichiro Suzuki et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
- (2021) Luckson N. Mathieu et al. CLINICAL CANCER RESEARCH
- Amivantamab: First Approval
- (2021) Yahiya Y. Syed DRUGS
- Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
- (2021) Mohamad Moussa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
- (2021) Mariam Elshiaty et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma
- (2021) Morgan Guénolé et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
- (2021) Liangxing Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib
- (2021) Viola W. Zhu et al. Journal of Thoracic Oncology
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- CAR T-cell therapy for solid tumours
- (2021) The Lancet Oncology LANCET ONCOLOGY
- Highly accurate protein structure prediction with AlphaFold
- (2021) John Jumper et al. NATURE
- Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
- (2021) Nicholas A. Vitanza et al. NATURE MEDICINE
- PI3K inhibitors are finally coming of age
- (2021) Bart Vanhaesebroeck et al. NATURE REVIEWS DRUG DISCOVERY
- Recent Advances in the Treatment of Melanoma
- (2021) Brendan D. Curti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on the Treatment of Malignant Pleural Mesothelioma
- (2021) Sam M. Janes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
- (2021) Yu He et al. PHARMACOLOGICAL RESEARCH
- Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
- (2021) James T. Coates et al. Cancer Discovery
- A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
- (2021) Prasad S Adusumilli et al. Cancer Discovery
- HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
- (2021) Ilana Schlam et al. npj Breast Cancer
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Mobocertinib: First Approval
- (2021) Anthony Markham DRUGS
- Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
- (2021) Mark Yarmarkovich et al. NATURE
- The PROTAC gold rush
- (2021) Ken Garber NATURE BIOTECHNOLOGY
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
- (2021) Patrick M. Forde et al. NATURE MEDICINE
- Oncolytic virotherapy as immunotherapy
- (2021) Alan Melcher et al. SCIENCE
- Endometrial cancer
- (2021) Vicky Makker et al. Nature Reviews Disease Primers
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
- (2021) Caicun Zhou et al. JAMA Oncology
- G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
- (2020) Kaitlyn J. Andreano et al. BREAST CANCER RESEARCH AND TREATMENT
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
- (2020) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Avapritinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Inhibitors of the protein–protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line
- (2020) Daisuke Yasuda et al. FREE RADICAL RESEARCH
- Enhanced metastable state models of TAM kinase binding to cabozantinib explains the dynamic nature of receptor tyrosine kinases
- (2020) Gatta K R S Naresh et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
- (2020) Michael R Migden et al. LANCET ONCOLOGY
- 2019 FDA drug approvals
- (2020) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- mTOR at the nexus of nutrition, growth, ageing and disease
- (2020) Grace Y. Liu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
- (2020) Ciara M. Kelly et al. JAMA Oncology
- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine
- (2020) Adriana C. Gamboa et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- Epigenetic Therapy for Epithelioid Sarcoma
- (2020) Scott B. Rothbart et al. CELL
- Tazemetostat: First Approval
- (2020) Sheridan M. Hoy DRUGS
- Pemigatinib: First Approval
- (2020) Sheridan M. Hoy DRUGS
- Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma
- (2020) Juliet E. Wolford et al. GYNECOLOGIC ONCOLOGY
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
- (2020) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
- (2020) Jingran Ji et al. JOURNAL OF CLINICAL ONCOLOGY
- Targets and Antibody Formats for Immunotherapy of Neuroblastoma
- (2020) Jeong A. Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
- (2020) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Cross-resistance among next generation anti-androgen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer
- (2020) Jinge Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Microbiome analyses of blood and tissues suggest cancer diagnostic approach
- (2020) Gregory D. Poore et al. NATURE
- The SWI/SNF complex in cancer — biology, biomarkers and therapy
- (2020) Priya Mittal et al. Nature Reviews Clinical Oncology
- Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
- (2020) Holger Fischer et al. NEURO-ONCOLOGY
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
- (2020) Jiyeon Yun et al. Cancer Discovery
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
- (2020) Maria Lorenzi et al. Journal of Oncology
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
- (2020) Ghulam Rehman Mohyuddin et al. BMC CANCER
- Prostate Cancer 2020: “The Times They Are a’Changing”
- (2020) Alec Paschalis et al. CANCER CELL
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- Capmatinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Ripretinib: First Approval
- (2020) Sohita Dhillon DRUGS
- A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
- (2020) Mark C. Markowski et al. EUROPEAN UROLOGY
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
- (2020) Tanios S Bekaii-Saab et al. Future Oncology
- Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
- (2020) Eisuke Tomiyama et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
- (2020) Viola W. Zhu et al. Journal of Thoracic Oncology
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
- (2020) Michael C Heinrich et al. LANCET ONCOLOGY
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The immunology of renal cell carcinoma
- (2020) C. Marcela Díaz-Montero et al. Nature Reviews Nephrology
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- (2020) J.J. Lin et al. ANNALS OF ONCOLOGY
- Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
- (2020) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Lurbinectedin: First Approval
- (2020) Anthony Markham DRUGS
- N‐glycosylation of PD‐1 promotes binding of camrelizumab
- (2020) Kefang Liu et al. EMBO REPORTS
- Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
- (2020) Mrinal Gounder et al. LANCET ONCOLOGY
- Epidemiology, definition and treatment of complicated urinary tract infections
- (2020) Florian M. E. Wagenlehner et al. Nature Reviews Urology
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
- (2020) Shaily Arora et al. ONCOLOGIST
- Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain
- (2020) Susanne Grunewald et al. Cancer Discovery
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- 75P Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): A humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
- (2020) J. Mora et al. ANNALS OF ONCOLOGY
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- (2020) C. Louwrens Braal et al. DRUGS
- The biology and rationale of targeting nectin-4 in urothelial carcinoma
- (2020) Elisabeth I. Heath et al. Nature Reviews Urology
- Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
- (2020) Domenica Lorusso et al. Targeted Oncology
- Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- (2020) Ian M. Silverman et al. Cancer Discovery
- Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
- (2020) Timothy F. Cloughesy et al. JAMA Oncology
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Extensive functional evaluation of exon 20 insertion mutations of EGFR
- (2020) Takeshi Hirose et al. LUNG CANCER
- Neratinib in HER2-Positive Breast Cancer Patients
- (2019) Rutugandha Paranjpe et al. ANNALS OF PHARMACOTHERAPY
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer
- (2019) Khine Myint et al. Scientific Reports
- TRK Inhibitors: Clinical Development of Larotrectinib
- (2019) Munveer S. Bhangoo et al. Current Oncology Reports
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microbiome, cancer, and cancer therapy
- (2019) Beth A. Helmink et al. NATURE MEDICINE
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- (2019) Paul Nghiem et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
- (2019) Sabrina Baltschukat et al. CLINICAL CANCER RESEARCH
- The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination
- (2019) Weixing Zhao et al. Annual Review of Biochemistry
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
- (2019) Jo Ishizawa et al. CANCER CELL
- Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
- (2019) Bryan D. Smith et al. CANCER CELL
- Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.
- (2019) Jaume Mora et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- (2019) Yusoo Lee et al. Journal of Thoracic Oncology
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
- (2019) Jane Guan et al. CELL
- Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
- (2019) Matteo Ligorio et al. CELL
- Targeting Topoisomerase I in the Era of Precision Medicine
- (2019) Anish Thomas et al. CLINICAL CANCER RESEARCH
- Erdafitinib: First Global Approval
- (2019) Anthony Markham DRUGS
- Entrectinib: First Global Approval
- (2019) Zaina T. Al-Salama et al. DRUGS
- Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
- (2019) Toshio Fujino et al. Journal of Thoracic Oncology
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- (2019) William D Tap et al. LANCET
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
- (2019) Kathryn C. Arbour et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
- (2019) Daphné Morel et al. Nature Reviews Clinical Oncology
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast cancer
- (2019) Nadia Harbeck et al. Nature Reviews Disease Primers
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- LBA28Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
- (2019) R C Doebele et al. ANNALS OF ONCOLOGY
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Modeling tumor evolutionary dynamics to predict clinical outcomes for patients with metastatic colorectal cancer: a retrospective analysis
- (2019) Jiawei Zhou et al. CANCER RESEARCH
- Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
- (2019) Gonzalo Recondo et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
- (2019) Carlos Murga-Zamalloa et al. CLINICAL CANCER RESEARCH
- Pexidartinib: First Approval
- (2019) Yvette N. Lamb DRUGS
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Breast cancer drug approvals by the US FDA from 1949 to 2018
- (2019) Chandra P. Leo et al. NATURE REVIEWS DRUG DISCOVERY
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
- (2019) Zuan-Fu Lim et al. Journal of Hematology & Oncology
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- (2019) Brian A. Lanman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model
- (2019) Suzanne P. MacFarland et al. MOLECULAR CANCER THERAPEUTICS
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
- (2019) Keelan Z. Guiley et al. SCIENCE
- Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis
- (2019) Shin Kedashiro et al. Scientific Reports
- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- P-161FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study
- (2018) I Cho et al. ANNALS OF ONCOLOGY
- nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
- (2018) D A Yardley et al. ANNALS OF ONCOLOGY
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
- (2018) Stephen J. Russell et al. CANCER CELL
- Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
- (2018) George E. Duran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma
- (2018) Vinod Varki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
- (2018) Renata Duchnowska et al. CANCER TREATMENT REVIEWS
- Casein kinase 1α: biological mechanisms and theranostic potential
- (2018) Shaojie Jiang et al. Cell Communication and Signaling
- Overcoming the resistance mechanisms of Smoothened inhibitors
- (2018) Xiaochun Dong et al. DRUG DISCOVERY TODAY
- Regorafenib: A Review in Metastatic Colorectal Cancer
- (2018) Sohita Dhillon DRUGS
- Olaratumab in soft tissue sarcoma – Current status and future perspectives
- (2018) Georgios Antoniou et al. EUROPEAN JOURNAL OF CANCER
- Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA -mutated ( BRCA m) platinum-sensitive relapsed ovarian
- (2018) A. Sackeyfio et al. GYNECOLOGIC ONCOLOGY
- Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway
- (2018) Yan Zhang et al. HUMAN PATHOLOGY
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and Molecular Spectrum of Liposarcoma
- (2018) Alex Thomas John Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Soft Tissue and Uterine Leiomyosarcoma
- (2018) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- (2018) Jessica J. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer
- (2018) Jonathan W. Riess et al. Journal of Thoracic Oncology
- The incidence of brain metastases in stage IV ROS1 -rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib
- (2018) Tejas Patil et al. Journal of Thoracic Oncology
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
- (2018) Sabino De Placido et al. LANCET ONCOLOGY
- EMA guidance on radium-223 dichloride in prostate cancer
- (2018) Elizabeth Gourd LANCET ONCOLOGY
- Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
- (2018) Rashmi Murthy et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- (2018) Benjamin A Teply et al. LANCET ONCOLOGY
- The dTAG system for immediate and target-specific protein degradation
- (2018) Behnam Nabet et al. Nature Chemical Biology
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- Temozolomide for immunomodulation in the treatment of glioblastoma
- (2018) Aida Karachi et al. NEURO-ONCOLOGY
- MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
- (2018) Hideaki ABE et al. NEUROLOGIA MEDICO-CHIRURGICA
- Breast Cancer in Men
- (2018) Sharon H. Giordano NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria
- (2018) Christine M. Dejea et al. SCIENCE
- CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors
- (2018) Clemens Reinshagen et al. Science Translational Medicine
- A secondary RET mutation in the activation loop conferring resistance to vandetanib
- (2018) Takashi Nakaoku et al. Nature Communications
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?
- (2018) Kulmira Nurgali et al. Frontiers in Pharmacology
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Encorafenib and Binimetinib: First Global Approvals
- (2018) Matt Shirley DRUGS
- Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.
- (2018) Markus Joerger et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
- (2018) Gonzalo Recondo et al. Nature Reviews Clinical Oncology
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on Keratinocyte Carcinomas
- (2018) Kishwer S. Nehal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolytic virus-mediated RAS targeting in rhabdomyosarcoma
- (2018) Michael P. Phelps et al. Molecular Therapy-Oncolytics
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- 900PInterim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
- (2018) A Necchi et al. ANNALS OF ONCOLOGY
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Gastroenteropancreatic Neuroendocrine Tumors
- (2018) Mauro Cives et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cemiplimab: First Global Approval
- (2018) Anthony Markham et al. DRUGS
- Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
- (2018) Gang Shi et al. MOLECULAR THERAPY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Intracellular Delivery of Antibodies: The State of the Art
- (2018) Tatiana A. Slastnikova et al. Frontiers in Pharmacology
- Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma
- (2018) Brian H. Kushner et al. JAMA Oncology
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Nectin-4 is a breast cancer stem cell marker that induces WNT/β-catenin signaling via Pi3k/Akt axis
- (2017) Sumit Siddharth et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
- (2017) Atrish Bagchi et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
- (2017) Jayaprakash D. Karkera et al. MOLECULAR CANCER THERAPEUTICS
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib
- (2017) David L. Hughes ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- A precision therapy against cancers driven by KIT/PDGFRA mutations
- (2017) Erica K. Evans et al. Science Translational Medicine
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
- (2017) Petros Fessas et al. SEMINARS IN ONCOLOGY
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Merkel cell carcinoma
- (2017) Jürgen C. Becker et al. Nature Reviews Disease Primers
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth
- (2016) Yijian Zhang et al. CANCER LETTERS
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
- (2016) Kefang Liu et al. CELL RESEARCH
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies
- (2016) D. L. van der Velden et al. CLINICAL CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes
- (2016) Harinath Doodhi et al. CURRENT BIOLOGY
- Necitumumab: First Global Approval
- (2016) Karly P. Garnock-Jones DRUGS
- Atezolizumab: First Global Approval
- (2016) Anthony Markham DRUGS
- Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
- (2016) Celeste B. Burness et al. DRUGS
- Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody
- (2016) H. Laken et al. EUROPEAN JOURNAL OF CANCER
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Olaratumab in soft-tissue sarcomas
- (2016) Winette T A van der Graaf LANCET
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Thyroid cancer
- (2016) Maria E Cabanillas et al. LANCET
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
- (2016) William D Tap et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form
- (2016) Marie-Christine Copin et al. LUNG CANCER
- High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
- (2016) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
- (2016) Katharine D. Grugan et al. mAbs
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
- (2016) I. C. Waizenegger et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Defining the clonal dynamics leading to mouse skin tumour initiation
- (2016) Adriana Sánchez-Danés et al. NATURE
- Structural basis of Smoothened regulation by its extracellular domains
- (2016) Eamon F. X. Byrne et al. NATURE
- Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
- (2016) Yufang Shi et al. NATURE REVIEWS DRUG DISCOVERY
- Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
- (2016) Yves Pommier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Adaptive Randomization of Neratinib in Early Breast Cancer
- (2016) John W. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity
- (2016) Michal Wieczorek et al. Science Translational Medicine
- Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223
- (2016) Robert Coleman SEMINARS IN NUCLEAR MEDICINE
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
- (2016) E. Allen Sickmier et al. PLoS One
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
- (2015) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Hepatitis B vaccination and prevention of hepatocellular carcinoma
- (2015) Jia-Horng Kao BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma
- (2015) Scott X. Atwood et al. CANCER CELL
- Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma
- (2015) Hayley J. Sharpe et al. CANCER CELL
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- TAS-102, a novel antitumor agent: A review of the mechanism of action
- (2015) Heinz-Josef Lenz et al. CANCER TREATMENT REVIEWS
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
- (2015) S. Arena et al. CLINICAL CANCER RESEARCH
- A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
- (2015) A. Drilon et al. CLINICAL CANCER RESEARCH
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
- (2015) C. Danial et al. CLINICAL CANCER RESEARCH
- Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data
- (2015) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Sonidegib: First Global Approval
- (2015) Celeste B. Burness DRUGS
- Cobimetinib: First Global Approval
- (2015) Karly P. Garnock-Jones DRUGS
- Axitinib: A Review in Advanced Renal Cell Carcinoma
- (2015) Gillian M. Keating DRUGS
- Talimogene Laherparepvec: First Global Approval
- (2015) Sarah L. Greig DRUGS
- Olaparib: First Global Approval
- (2015) Emma D. Deeks DRUGS
- Dinutuximab: First Global Approval
- (2015) Sohita Dhillon DRUGS
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- Disialoganglioside GD2 as a therapeutic target for human diseases
- (2015) Maya Suzuki et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma
- (2015) Scott X. Atwood et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
- (2015) Bing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms
- (2015) Venkata K. Pokuri et al. Journal of the National Comprehensive Cancer Network
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody
- (2015) Irena Horwacik et al. MOLECULAR & CELLULAR PROTEOMICS
- High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
- (2015) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
- (2015) William D. Tap et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204
- (2015) J. C. Landry et al. ONCOLOGIST
- Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
- (2015) Monika A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
- (2015) C. C. Smith et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
- (2015) Howard W. Rogers et al. JAMA Dermatology
- Non-small-cell lung cancer
- (2015) Cesare Gridelli et al. Nature Reviews Disease Primers
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
- (2015) Brooke E. Howitt et al. JAMA Oncology
- Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles
- (2015) Khine Myint et al. PLoS One
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Transgenic Expression of the Human MRP2 Transporter Reduces Cisplatin Accumulation and Nephrotoxicity in Mrp2-Null Mice
- (2014) Xia Wen et al. AMERICAN JOURNAL OF PATHOLOGY
- Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
- (2014) Pernelle Lavaud et al. BMC Medicine
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
- (2014) David F. McDermott et al. CLINICAL CANCER RESEARCH
- MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
- (2014) H.-U. Schildhaus et al. CLINICAL CANCER RESEARCH
- Degarelix: A Review of Its Use in Patients with Prostate Cancer
- (2014) Natalie J. Carter et al. DRUGS
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer
- (2014) Sheridan M. Hoy DRUGS
- Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
- (2014) Matt Shirley et al. DRUGS
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation
- (2014) Xuelai Fan et al. NATURE NEUROSCIENCE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
- (2014) NOZOMU TANAKA et al. ONCOLOGY REPORTS
- Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization
- (2014) Kiyoshi Okamoto et al. ACS Medicinal Chemistry Letters
- Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs
- (2014) Chong Wang et al. Nature Communications
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets
- (2014) Christine Spitzweg et al. Lancet Diabetes & Endocrinology
- Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
- (2014) Mika Aoyagi-Scharber et al. Acta Crystallographica Section F-Structural Biology Communications
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
- (2013) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
- (2013) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel
- (2013) Philippa Cheetham et al. CANCER JOURNAL
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies
- (2013) Patrizia Limonta et al. CANCER TREATMENT REVIEWS
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
- (2013) B. N. Rexer et al. CLINICAL CANCER RESEARCH
- EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
- (2013) F. Bladt et al. CLINICAL CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
- (2013) John D. Hainsworth et al. Clinical Genitourinary Cancer
- Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review
- (2013) Michael K. Wong et al. CURRENT MEDICAL RESEARCH AND OPINION
- Trametinib: First Global Approval
- (2013) Cameron J. M. Wright et al. DRUGS
- Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2013) Sheridan M. Hoy DRUGS
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
- (2013) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
- (2013) Richard A. Ward et al. JOURNAL OF MEDICINAL CHEMISTRY
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Structural basis for molecular recognition of folic acid by folate receptors
- (2013) Chen Chen et al. NATURE
- Drug for an 'undruggable' protein
- (2013) Nicole M. Baker et al. NATURE
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
- (2013) A. F. Labrijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
- (2013) A. E. Prota et al. SCIENCE
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Dye Sensitizers for Photodynamic Therapy
- (2013) Alexandra Ormond et al. Materials
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- (2013) E. J. Lipson et al. Cancer Immunology Research
- Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
- (2012) Anne Lynn S. Chang et al. ARCHIVES OF DERMATOLOGY
- Androgen deprivation therapy: past, present and future
- (2012) F. Schröder et al. BJU INTERNATIONAL
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Vismodegib
- (2012) C. M. Rudin CLINICAL CANCER RESEARCH
- Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
- (2012) K. Inoue et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeted -Particle Radiation Therapy
- (2012) K. E. Baidoo et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Vinorelbine in Cancer Therapy
- (2012) Anna Capasso CURRENT DRUG TARGETS
- Vandetanib
- (2012) James E. Frampton DRUGS
- Docetaxel
- (2012) Kate McKeage DRUGS
- Neuroendocrine tumor disease: an evolving landscape
- (2012) Andrea Frilling et al. ENDOCRINE-RELATED CANCER
- Temsirolimus: a safety and efficacy review
- (2012) Ronald M. Bukowski Expert Opinion On Drug Safety
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma
- (2012) Gergő Papp et al. MODERN PATHOLOGY
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
- (2012) Natasha M. DeVore et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Ziv-aflibercept: binding to more than VEGF-A—does more matter?
- (2012) Jeffrey M. Clarke et al. Nature Reviews Clinical Oncology
- Vismodegib
- (2012) Andrzej Dlugosz et al. NATURE REVIEWS DRUG DISCOVERY
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
- (2012) Ujjal Mallick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- Concise Drug Review: Pazopanib and Axitinib
- (2012) R. M. J. M. van Geel et al. ONCOLOGIST
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Medullary Thyroid Carcinoma: Who's on First?
- (2012) Mimi I. Hu et al. THYROID
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
- (2012) Nai-Kong V. Cheung et al. OncoImmunology
- Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
- (2011) P. Karlsson et al. ANNALS OF ONCOLOGY
- The clinical development of inhibitors of poly(ADP-ribose) polymerase
- (2011) H. Calvert et al. ANNALS OF ONCOLOGY
- Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer
- (2011) Neal Shore et al. BJU INTERNATIONAL
- Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
- (2011) Emiliano Cocco et al. BMC CANCER
- Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
- (2011) E Giovannetti et al. BRITISH JOURNAL OF CANCER
- Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
- (2011) J Geisler BRITISH JOURNAL OF CANCER
- Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody
- (2011) Joyce Varughese et al. CANCER
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Shmt1 Heterozygosity Impairs Folate-Dependent Thymidylate Synthesis Capacity and Modifies Risk of Apcmin-Mediated Intestinal Cancer Risk
- (2011) A. J. MacFarlane et al. CANCER RESEARCH
- Direct spectroscopic evidence for binding of anastrozole to the iron heme of human aromatase. Peering into the mechanism of aromatase inhibition
- (2011) Sara Maurelli et al. CHEMICAL COMMUNICATIONS
- Natural Taxanes: Developments Since 1828
- (2011) Yu-Fang Wang et al. CHEMICAL REVIEWS
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Cabazitaxel
- (2011) Cristian Villanueva et al. DRUGS
- Vandetanib
- (2011) Helen Commander et al. DRUGS
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
- (2011) Charles E Massie et al. EMBO JOURNAL
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to RAF Inhibitors in Melanoma
- (2011) Andrew E. Aplin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor
- (2011) Kazuhiro Miwa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer
- (2011) E. David Crawford et al. JOURNAL OF UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
- (2011) A Urbanucci et al. ONCOGENE
- Binding features of steroidal and nonsteroidal inhibitors
- (2011) Yanyan Hong et al. STEROIDS
- The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies
- (2011) Matthew C. Franklin et al. STRUCTURE
- A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
- (2011) Ulf W Tunn BMC Urology
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
- (2010) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
- (2010) JFM Leal et al. BRITISH JOURNAL OF PHARMACOLOGY
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
- (2010) N. R. Smith et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)
- (2010) C. Romei et al. CLINICAL ENDOCRINOLOGY
- Trabectedin
- (2010) Natalie J. Carter et al. DRUGS
- Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors
- (2010) Kyungik Lee et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database
- (2010) Samuel Murray et al. Journal of Thoracic Oncology
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Malignant Pleural Mesothelioma: A Population-Based Study of Survival
- (2010) Michael T. Milano et al. Journal of Thoracic Oncology
- Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
- (2010) Marta Salido et al. Journal of Thoracic Oncology
- Non-melanoma skin cancer
- (2010) Vishal Madan et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Cabazitaxel
- (2010) Matthew D. Galsky et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Advances in Neuroblastoma
- (2010) John M. Maris NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
- (2009) G. Attard et al. CANCER RESEARCH
- Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
- (2009) A. Takano et al. CANCER RESEARCH
- The BRAFV600E Oncogene Induces Transforming Growth Factor Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer
- (2009) G. Riesco-Eizaguirre et al. CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Alitretinoin
- (2009) Karly P. Garnock-Jones et al. DRUGS
- Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis
- (2009) Cristina Rodríguez-Antona et al. ENDOCRINE-RELATED CANCER
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Tissue Factor in Cancer
- (2009) Raj S. Kasthuri et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Pazopanib
- (2009) Ronald M. Bukowski et al. NATURE REVIEWS DRUG DISCOVERY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
- (2009) R. L. Yauch et al. SCIENCE
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations
- (2009) Joseph P. Boni et al. SEMINARS IN ONCOLOGY
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells
- (2008) Muralidhar L Hegde et al. CELL RESEARCH
- Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels
- (2008) J. Geisler et al. CLINICAL CANCER RESEARCH
- Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
- (2008) B. I. Rini CLINICAL CANCER RESEARCH
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Bevacizumab
- (2008) Paul L McCormack et al. DRUGS
- BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer
- (2008) C. Romei et al. ENDOCRINE-RELATED CANCER
- Guidelines for the clinical management of familial adenomatous polyposis (FAP)
- (2008) H. F. A. Vasen et al. GUT
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor†
- (2008) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare
- (2008) Maarten F Corsten et al. LANCET ONCOLOGY
- Diagnosis of Poorly Differentiated Thyroid Cancer with Radioiodine Scanning after Thyrotropin Alfa Stimulation
- (2008) Malik Juweid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Will GnRH antagonists improve prostate cancer treatment?
- (2008) Ilpo Huhtaniemi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
- (2007) Matthew D. Hall et al. Annual Review of Pharmacology and Toxicology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started